Patient outcomes
| Outcome . | Filgrastim . | Placebo . | P Value . |
|---|---|---|---|
| RBC transfusions | |||
| Median | 6 | 6 | .94 |
| Range | 0-52 | 0-50 | |
| Platelet transfusions | |||
| Median | 7.5 | 8.0 | .84 |
| Range | 1-78 | 3-50 | |
| 100-d survival | 73% | 83% | .50 |
| GVHD | |||
| Acute | (n = 25) | (n = 23) | |
| Overall | 68% | 78% | .58 |
| Grade II-IV | 48% | 61% | .41 |
| Grade III-IV | 30% | 12% | .11 |
| Chronic | (n = 20) | (n = 19) | |
| Overall | 58% | 45% | .53 |
| Extensive | 21% | 35% | .48 |
| Outcome . | Filgrastim . | Placebo . | P Value . |
|---|---|---|---|
| RBC transfusions | |||
| Median | 6 | 6 | .94 |
| Range | 0-52 | 0-50 | |
| Platelet transfusions | |||
| Median | 7.5 | 8.0 | .84 |
| Range | 1-78 | 3-50 | |
| 100-d survival | 73% | 83% | .50 |
| GVHD | |||
| Acute | (n = 25) | (n = 23) | |
| Overall | 68% | 78% | .58 |
| Grade II-IV | 48% | 61% | .41 |
| Grade III-IV | 30% | 12% | .11 |
| Chronic | (n = 20) | (n = 19) | |
| Overall | 58% | 45% | .53 |
| Extensive | 21% | 35% | .48 |
RBC indicates red blood cell; GVHD, graft-versus-host disease.